$10.20
-0.48[-4.49%]
At close: Apr 18
$10.20
0[0.00%]
After Hours: 7:00PM EDT
ITeos Therapeutics
(NASDAQ:ITOS)ITeos Therapeutics Stock (NASDAQ:ITOS), Analyst Ratings, Price Targets, Predictions
ITeos Therapeutics Inc has a consensus price target of $41.17, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, HC Wainwright & Co., and JP Morgan on March 12, 2024, March 7, 2024, and November 13, 2023. With an average price target of $33.33 between JP Morgan, HC Wainwright & Co., and JP Morgan, there's an implied 226.80% upside for ITeos Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
HC Wainwright & Co.
JP Morgan
Wedbush
SVB Leerink
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ITeos Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/12/2024 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 164.71% | JP Morgan | Brian Cheng | $29 → $27 | Maintains | Overweight | Get Alert |
| 03/07/2024 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 331.37% | HC Wainwright & Co. | Swayampakula Ramakanth | → $44 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2023 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 184.31% | JP Morgan | Daniel Wolle | $32 → $29 | Maintains | Overweight | Get Alert |
| 10/18/2023 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 223.53% | Wedbush | David Nierengarten | → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 331.37% | HC Wainwright & Co. | Swayampakula Ramakanth | $54 → $44 | Maintains | Buy | Get Alert |
| 03/17/2023 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 429.41% | HC Wainwright & Co. | Swayampakula Ramakanth | → $54 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 213.73% | JP Morgan | Daniel Wolle | $34 → $32 | Maintains | Overweight | Get Alert |
| 03/16/2023 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 223.53% | Wedbush | David Nierengarten | $45 → $33 | Maintains | Outperform | Get Alert |
| 05/13/2022 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 478.43% | SVB Leerink | Daina Graybosch | $60 → $59 | Maintains | Outperform | Get Alert |
| 12/13/2021 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 429.41% | HC Wainwright & Co. | Swayampakula Ramakanth | — | Maintains | Buy | Get Alert |
| 11/12/2021 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 429.41% | SVB Leerink | Daina Graybosch | — | Maintains | Outperform | Get Alert |
| 08/13/2021 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 439.22% | SVB Leerink | — | — | Maintains | Outperform | Get Alert |
| 05/19/2021 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 341.18% | SVB Leerink | — | — | Maintains | Outperform | Get Alert |
| 05/05/2021 | ITOS | Buy Now | ITeos Therapeutics | $10.20 | 262.75% | HC Wainwright & Co. | Swayampakula Ramakanth | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for ITeos Therapeutics (ITOS)?
The latest price target for ITeos Therapeutics (NASDAQ: ITOS) was reported by JP Morgan on March 12, 2024. The analyst firm set a price target for $27.00 expecting ITOS to rise to within 12 months (a possible 164.71% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ITeos Therapeutics (ITOS)?
The latest analyst rating for ITeos Therapeutics (NASDAQ: ITOS) was provided by JP Morgan, and ITeos Therapeutics maintained their overweight rating.
When was the last upgrade for ITeos Therapeutics (ITOS)?
There is no last upgrade for ITeos Therapeutics.
When was the last downgrade for ITeos Therapeutics (ITOS)?
There is no last downgrade for ITeos Therapeutics.
When is the next analyst rating going to be posted or updated for ITeos Therapeutics (ITOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ITeos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ITeos Therapeutics was filed on March 12, 2024 so you should expect the next rating to be made available sometime around March 12, 2025.
Is the Analyst Rating ITeos Therapeutics (ITOS) correct?
While ratings are subjective and will change, the latest ITeos Therapeutics (ITOS) rating was a maintained with a price target of $29.00 to $27.00. The current price ITeos Therapeutics (ITOS) is trading at is $10.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.